Montefiore Health System and Einstein bank $ 111 million to lead group focused on HIV-related cancers
“People living with HIV bear a huge burden of cancer,” said Dr. Joseph Sparano, associate chair of clinical research at the Montefiore Department of Oncology, associate director of clinical research at the Albert Einstein Cancer Center and principal investigator of the grant, in a report. “AMC is the only organization in the world fully dedicated to the study, treatment and prevention of cancer in this group of people. “
The next step
The AIDS Malignancy Consortium oversees a network of 42 clinical trial sites in the United States, Africa and Latin America, as well as scientists who support its trials, noted Montefiore and Einstein.
He also runs a career program to help the next generation of leaders in the region receive resources and support. He works directly with people living with HIV and cancer to help better identify the needs of the community.
The results of its clinical trials have helped strengthen treatment guidelines as well as advance the prevention and management of cancers associated with the human papillomavirus and the use of precision medicine and immunotherapy for people. living with HIV who are receiving antiretroviral therapy, Montefiore and Einstein said.
“In this next phase, we will build on these successes, developing and conducting additional clinical trials designed to meet the most critical needs of people living with HIV and cancer, precancerous diseases and those with high risk of cancer. “, added Sparano.
The Anchor study focuses on the prevention and treatment of anal cancer caused by HPV. Dr. Rebecca Levine, Assistant Professor of Surgery at Einstein and Surgical Oncologist at Montefiore, is the Principal Investigator Anchor at Einstein and Montefiore.
“We expect the results of this study to have a huge impact on clinical care,” Levine said in a statement.
The AIDS Malignancy Consortium was previously led by the University of California, Los Angeles.